Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVS crawled time : 06:00 save search
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
kesimpta sclerosis novartis show benefits
Positron Emission Tomography Market size is set to grow by USD 725.97 mn from 2024-2028,increasing prevalence of chronic conditions worldwide boost the market- Technavio
Published: 2024-04-03 (Crawled : 06:00) - prnewswire.com
CAJPY | $28.73 -0.28% -0.41% 38K
|
n/a
|
| O: -0.3%
H: 0.54%
C: 0.54%
CAJFF | $29.0664 -28.15% 760
|
Electronic Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
NVSEF | News | $96.0 0.94% 6.88% 52K
|
Health Technology
|
| O: -2.86%
H: 0.17%
C: 0.17%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: 0.04%
H: 0.46%
C: -0.08%
PHG | News | $21.01 1.94% 0.0% 2M
|
Health Technology
|
| O: 1.0%
H: 0.0%
C: 0.0%
worldwide set market
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Published: 2024-01-31 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
sales year momentum positive innovation novartis growth
Obsessive-Compulsive Disorder Drugs Market size worth USD 348.54 million, 55% Growth to Originate from North America - Technavio
Published: 2024-01-25 (Crawled : 06:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K
|
Health Technology
|
| O: -3.67%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -0.44%
H: 0.19%
C: -0.08%
GSK | News | $41.24 1.6% -0.58% 2.1M
|
Health Technology
|
| O: -0.23%
H: 0.03%
C: -0.26%
JAZZ | $109.67 0.77% 0.78% 380K
|
Health Technology
|
| O: 0.28%
H: 0.36%
C: -0.53%
BWAY | $4.935 3.9% 2.86% 28K
|
Health Technology
|
| O: 1.47%
H: 0.65%
C: -1.45%
america growth market
Antimicrobial Therapeutics Market to grow by USD 51.4 billion from 2022 to 2027, North America accounts for 38% of market growth- Technavio
Published: 2024-01-17 (Crawled : 06:00) - prnewswire.com
CSLLY | $90.71 1.73% 3.3% 34K
|
n/a
|
| O: -0.64%
H: 0.54%
C: 0.54%
GLAXF | News | $19.54 -3.77% -14.18% 2.6K
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 -0.42% -1.11% 480K
|
Manufacturing
|
| O: -1.74%
H: 0.0%
C: -1.35%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: 0.49%
H: 0.18%
C: 0.04%
GSK | News | $41.24 1.6% -0.58% 2.1M
|
Health Technology
|
| O: -0.08%
H: 0.1%
C: -0.18%
ABBV | News | $169.54 0.98% 0.18% 3.2M
|
Health Technology
|
| O: -0.15%
H: 0.74%
C: 0.18%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
america therapeutics market
Radiopharmaceuticals market size to grow by USD 4.37 billion from 2021 to 2026 | Actinium Pharmaceuticals Inc., Bayer AG, Bracco Spa, BWX Technologies Inc. and more among the key companies in the market - Technavio
Published: 2023-12-12 (Crawled : 06:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K
|
Health Technology
|
| O: 1.56%
H: 0.51%
C: 0.51%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: 0.45%
H: 0.75%
C: 0.46%
FUSN | $21.42 0.47% 0.47% 1.9M
|
Health Technology
|
| O: 2.01%
H: 4.73%
C: 3.55%
companies pharmaceuticals market
Open-Angle Glaucoma Therapeutics Market size to grow by USD 2.36 billion from 2022 to 2027, North America to account for 51% of market growth - Technavio
Published: 2023-11-28 (Crawled : 06:00) - prnewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -0.54%
H: 0.08%
C: -0.22%
BHC | $8.53 0.95% 0.0% 4M
|
Health Technology
|
| O: -0.73%
H: 1.17%
C: 0.29%
ALC | $80.76 0.19% 0.0% 880K
|
Health Technology
|
| O: -0.14%
H: 1.24%
C: 0.53%
ABBV | News | $169.54 0.98% 0.18% 3.2M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
america glaucoma therapeutics growth market
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
Published: 2023-11-28 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -0.54%
H: 0.08%
C: -0.22%
day sales pipeline novartis growth
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
Published: 2023-10-05 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -1.21%
H: 1.3%
C: 1.16%
breast innovation cancer novartis
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
Published: 2023-10-02 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: 0.19%
H: 0.03%
C: -0.5%
nephropathy novartis study
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K
|
Health Technology
|
| O: -3.05%
H: 1.75%
C: 0.5%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -0.07%
H: 0.46%
C: -0.31%
tyruko europe biosimilar approval sclerosis
Novartis confirms Sandoz Spin-off for October 4, 2023
Published: 2023-09-25 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K
|
Health Technology
|
| O: 3.72%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -0.31%
H: 0.98%
C: 0.97%
novartis
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Published: 2023-09-25 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K
|
Health Technology
|
| O: 3.72%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -0.31%
H: 0.98%
C: 0.97%
lutathera tumors novartis therapy
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Published: 2023-09-18 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -1.31%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: 0.06%
H: 0.09%
C: -0.6%
biosimilar chmp breast positive cancer
Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis
Published: 2023-09-06 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: 0.0%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -0.35%
H: 0.31%
C: 0.14%
international commercial novartis
Sandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statements
Published: 2023-09-05 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 52K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -0.73%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -1.17%
H: 0.02%
C: -1.46%
financial
Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
Published: 2023-08-28 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: 1.06%
H: 0.06%
C: -0.51%
mycamine acquisition global antifungal
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Published: 2023-08-25 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: 0.67%
H: 0.37%
C: 0.26%
tyruko fda biosimilar approval sclerosis
Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote
Published: 2023-08-18 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -0.72%
H: 0.43%
C: 0.02%
novartis
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
Published: 2023-08-15 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.44%
biosimilar positive results study
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.